Per(poly)fluoroalkanesulfinamides Assisted Diastereoselective Three-Component Inverse-Electron-Demand Aza Diels—Alder Reaction

Peng Li, Li-Juan Liu, and Jin-Tao Liu*.

Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.

jtliu@mail.sioc.ac.cn

Supplementary Information

Contents

General	S2
General procedure for the synthesis of per(poly)fluoroalkanesulfinamides 2a-2d	S2
General procedure for the preparation of tetrahydropyridines 4a-4v	S2
Transformations of cycloadducts	S7
Determination of the stereochemistry of the products	
References	S10
NMR Spectra	S11

General

Unless otherwise mentioned, solvents and reagents were purchased from commercial sources and used as received. THF was freshly distilled over Na/benzophenone, CH_2Cl_2 was distilled over CaH_2 . Melting points were measured on a Melt-Temp apparatus and uncorrected. ¹H NMR spectra were recorded on Bruker AM-300 or Mercury 300 (300 MHz) spectrometers with TMS as the internal standard. ¹⁹F NMR spectra were recorded on Bruker AM-300 or Mercury 300 or Mercury 300 (282 MHz) spectrometers with CFCl₃ as the external standard. ¹³C NMR spectra were recorded on DPX-400 (100.7 MHz) spectrometer. IR spectra were obtained with a Nicolet AV-360 spectrophotometer. Mass spectra were taken on a HP5989A spectrometer. HRMS data were obtained on a high-resolution mass spectrometer in the ESI or EI mode. α , β -Unsaturated ketones (aldehydes) were prepared according to the literature.¹

General Procedure for the Preparation of Perfluoroalkanesulfinamides 2a-2d.

To a flask containing $HN(SiMe_3)_2$ (16 mL, 0.075 mol) was added dropwise per(poly)fluoroalkanesulfinyl chloride (0.075 mol) at 0 °C. After addition, stirring was continued for 2 h at room temperature. The TMS substituted sulfinamide intermediate was obtained by distillation under reduced pressure, which was further stirred with saturated aqueous ammonium chloride solution and purified by short column chromatography to give the target product **2**.²

2-Chloro-1,1,2,2-tetrafluoroethanesulfinamide (2a): ¹H NMR (300 MHz, CDCl₃): δ 4.96 (s, 2H); ¹⁹F NMR (282 MHz, CDCl₃): δ -67.29 (m, 2F), -121.10 (dd, J_{4B} = 231.2 Hz, Δv = 3.45, 2F).

Trifluoromethanesulfinamide (2b): ¹H NMR (300 MHz, CDCl₃): δ 4.97 (s, 2H); ¹⁹F NMR (282 MHz, CDCl₃): δ -80.92 (s, 3F).

Difluoro(phenyl)methanesulfinamide (2c): ¹H NMR (300 MHz, CDCl₃): δ 7.62-7.50 (m, 5H), 4.00 (s, 2H); ¹⁹F NMR (282 MHz, CDCl₃): δ -105.04 (dd, J_{AB} = 226.4 Hz, Δv = 4.40, 2F).

Perfluorobutanesulfinamide (2d): ¹H NMR (300 MHz, CDCl₃): δ 4.86 (s, 2H); ¹⁹F NMR (282 MHz, CDCl₃): δ -81.22 (m, 3F), -121.93 (m, 2F), -122.46 (ddt, *J* = 430.3, 243.4, 8.46 Hz, 2F), -126.48 --126.55 (m, 2F).

(*S*_s)-2-Chloro-1,1,2,2-tetrafluoroethanesulfinamide (2a): A solution of 5³ (0.5 mmol) in CH₂Cl₂ (7 mL) was added slowly to LiHMDS (1 mmol) in CH₂Cl₂ (3 mL) in 3h at -78 °C under the protection of N₂. After addition, saturated ammonium chloride aqueous solution (5 mL) was added immediately. The resulting mixture was extracted with CH₂Cl₂ (5 mL×3), washed with brine (10 mL), dried over Na₂SO₄ and purified by silica gel chromatography (EtOAc/ Petroleum ether: 1/5) to afford a white solid (72% yield): mp 42-43 °C; $[\alpha]_D^{20} = -15.4542$ (*c* = 0.9850, CHCl₃, >99%ee).

General Procedure for the Preparation of Tetrahydropyridines 4a-4v.

To a solution of α , β -unsaturated ketone **1** (0.5 mmol), sulfinamide **2** (0.6 mmol) and vinyl ether **3** (1.0 mmol) in CH₂Cl₂ (1 mL), Ti(OPr^{*i*})₄ (1.5 mmol) was added and the resulting mixture was stirred in a sealed vial at room temperature and monitored by TLC. After reaction, the mixture was poured into an equal volume of brine with rapid stirring and filtered through celite. The filter cake was washed with CH₂Cl₂ (3 mL \times 3). The combined filtrate was washed with brine (6 mL), dried over Na₂SO₄. After the removal of solvents under vacuum, the residue was purified by column chromatography on silica gel to afford **4**.

4a-major endo: white solid, 147 mg, 65%; mp 55–57 °C; ¹H NMR (300 MHz, CDCl₃): δ 7.33–7.19 (5H, m, ArH), 6.25 (1H, d, J = 3.3 Hz, =CH), 5.52 (1H, s, NCHO), 3.68 (1H, dt, J = 8.7, 2.4 Hz, CHPh), 3.58 (1H, dq, J = 9.3, 6.9 Hz, OCHHCH₃), 3.37 (1H, dq, J = 9.3, 6.9 Hz, OCHHCH₃), 2.63 (1H, ddd, J = 14.7, 9.0, 3.3 Hz, CH_aH_e), 2.41 (1H, d, J = 14.7 Hz, CH_aH_e), 1.05 (3H, t, J = 6.9, OCH₂CH₃); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.38 (s, 3F), -67.88 (s, 2F), -116.51 (dd, J_{AB} = 226.4 Hz, Δv = 12.20, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 143.6, 128.7, 128.5, 127.0, 121.6 (m), 120.7 (q, J = 272.5 Hz), 76.5, 63.6, 35.7, 34.8, 14.8; FT-IR (KBr): v_{max}

2983, 2900, 1668, 1494, 1456, 1392, 1341, 1308, 1251, 1188, 1177, 1143, 1116, 1056, 952, 929, 786, 703 cm⁻¹; EIHRMS: *m/z* 453.0401 (M⁺, C₁₆H₁₅ClF₇NO₂ S requires 453.0400).

4b-major endo: colorless oil, 122 mg, 63%; ¹H NMR (300 MHz, CDCl₃): δ 7.39–7.20 (5H, m, ArH), 6.27 (1H, d, *J* = 3.6 Hz, =C*H*), 5.46 (1H, t, *J* = 2.7 Hz, NC*H*O), 3.71–3.69 (1H, m, C*H*Ph), 3.58 (1H, dq, *J* = 9.3, 6.9 Hz, OC*H*HCH₃), 3.37 (1H, dq, *J* = 9.3, 6.9 Hz,OC*H*HCH₃), 2.41 (2H, m, C*H*_a*H*_e), 1.05 (3H, t, *J* = 6.9, OCH₂C*H*₃); ¹⁹F NMR (282 MHz, CDCl₃): δ -63.95 (s, 3F), -73.97 (s, 3F); ¹³C NMR (100 MHz, CDCl₃): δ 143.2, 128.5, 128.4, 128.3, 121.6 (m), 120.7 (q, *J* = 272.2 Hz), 76.5, 63.4, 35.4, 34.6, 14.5; FT-IR (neat): v_{max} 2981, 1668, 1494, 1455, 1394, 1339, 1305, 1250, 1189, 1126, 1061, 9542, 932, 701 cm⁻¹; EIMS (*m*/*z*, %): 387 (M⁺, 1.34), 342 (2.52), 318 (34.25), 270 (2.92), 224 (48.42), 183 (100.00), 77 (8.44); EIHRMS: *m*/*z* 387.0731 (M⁺, C₁₅H₁₅F₆NO₂S requires 387.0728).

4c-major endo: white solid, 93.5 mg, 42%; mp 96–98 °C; ¹H NMR (300 MHz, CDCl₃): δ 7.63–7.46 (5H, m, ArH), 7.36–7.17 (5H, m, ArH), 6.21 (1H, d, *J* = 3.9 Hz, =*CH*), 5.57 (1H, t, *J* = 2.6 Hz, NCHO), 3.78–3.66 (1H, m, *CH*Ph), 3.60 (1H, dq, *J* = 9.3, 6.9 Hz, OC*H*HCH₃), 3.37 (1H, dq, *J* = 9.3, 6.9 Hz, OC*H*HCH₃), 2.62 (1H, ddd, *J* = 14.7, 9.3, 3.0 Hz, *CH_a*H_e), 2.41 (1H, d, *J* = 14.7 Hz, CH_aH_e), 1.04 (3H, t, *J* = 6.9, OCH₂*CH*₃); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.43 (s, 3F), -105.43 (dd, *J_{AB}* = 210.1 Hz, Δv =15.22, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 143.9, 131.9, 129.7, 129.0, 128.5, 128.2, 126.5, 126.0, 121.0 (q, *J* = 272.2 Hz), 119.9 (m), 76.0, 63.0, 35.6, 34.8, 14.7; FT-IR (KBr): v_{max} 3066, 3032, 2978, 1663, 1604, 1494, 1454, 1394, 1338, 1303, 1278, 1189, 1142, 1068, 956, 932, 888, 758, 699 cm⁻¹; EIMS (*m*/*z*, %): 445 (M⁺, 0.58), 400 (0.90), 270 (7.09), 225 (11.55), 183 (22.75), 127 (100.00), 77 (9.98); EIHRMS *m*/*z* 445.1131 (M⁺, C₂₁H₂₀F₅NO₂S requires 445.1135).

4d-major endo: colorless oil, 146.3 mg, 59%; ¹H NMR (300 MHz, CDCl₃): δ 7.39–7.13 (5H, m, ArH), 6.26 (1H, d, J = 3.6 Hz, =CH), 5.53 (1H, s, NCHO), 3.74–3.64 (1H, m, CHPh), 3.58 (1H, dq, J = 9.3, 6.9 Hz, OCHHCH₃), 3.37 (1H, dq, J = 9.3, 6.9 Hz,OCHHCH₃), 2.56–2.34 (2H, m, CH_aH_e), 1.06 (3H, t, J = 6.9, OCH₂CH₃); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.73 (s, 3F), -80.8–82.0 (m, 3F), -118.2 (dd, J_{AB} = 238.8 Hz, Δv = 12.34, 2F), -122.6 (s, 2F), -126.7 (t, J= 304.8 Hz, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 143.3, 128.4, 128.3, 126.8, 121.5 (m), 120.7 (q, J = 272.7 Hz), 76.2, 63.4, 35.5, 34.6, 14.5; FT-IR (neat): v_{max} 2982, 1668, 1605, 1495, 1394, 1350, 1339, 1304, 1240, 1195, 1139, 1143, 1061, 955, 932, 746, 700, 691 cm⁻¹; EIMS (m/z, %): 318 (M⁺ – C₄F₉, 32.86), 270 (6.36), 225 (23.42), 183 (100.00), 77 (21.12); EIHRMS: m/z 537.0636 (M⁺, C₁₈H₁₅F₁₂NO₂S requires 537.0632).

4e-major endo: colorless oil; 151.9 mg, 63%; ¹H NMR (300 MHz, CDCl₃): δ 7.35 – 7.17 (5H, m, ArH), 6.27 (1H, d, J = 3.6 Hz, =CH), 5.47 (1H, t, J = 2.4 Hz, NCHO), 3.75 - 3.65 (1H, m, CHPh), 3.31 (1H, dd, J = 9.3, 6.3 Hz, OCHHCH(CH₃)₂), 3.12 (1H, dd, J = 9.3, 6.0 Hz, OCHHCH(CH₃)₂), 2.52 (1H, ddd, J = 14.4, 9.0, 3.0 Hz, CH_aH_e), 2.45 (1H, d, J = 14.4 Hz, CH_aH_e), 1.74–1.58 (1H, m, OCH₂CH(CH₃)₂), 0.77 (3H, d, J = 6.3 Hz, OCH₂CH(CH₃)₂), 0.74 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.05 (s, 3F), -67.63 (dd, $J_{AB} = 183.3$ Hz, $\Delta v = 0.20$, 2F), -116.32 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.22$, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 143.4, 128.3, 128.2, 126.7, 121.2 (m), 120.7 (q, J = 272.5 Hz), 76.9, 76.8, 75.1, 35.2, 34.5, 28.1, 19.2, 19.1; FT-IR (neat): v_{max} 2961, 2875, 1666, 1604, 1494, 1473, 1454, 1394, 1340, 1303, 1250, 1180, 1140, 1057, 1013, 948, 929, 788, 701 cm⁻¹; HREIMS: *m/z* 481.0720 (M⁺, C₁₈H₁₉CIF₇NO₂S requires 481.0713).

4f-major endo: colorless oil; 161.3 mg, 67%; ¹H NMR (300 MHz, CDCl₃): δ 7.36–7.15 (5H, m, ArH), 6.26 (1H, d, *J* = 3.3 Hz, =C*H*), 5.49 (1H, s, NC*H*O), 3.71–3.67 (1H, m, *CHP*h), 3.53 (1H, dt, *J* = 9.6, 6.3 Hz, OC*H*HC₃H₇), 3.31 (1H, dt, *J* = 9.6, 6.3 Hz, OC*H*HC₃H₇), 2.51 (1H, ddd, *J* = 14.4, 9.0, 3.0 Hz, CH_aH_e), 2.42 (1H, d, *J* = 14.4 Hz, CH_aH_e), 1.45–1.31 (2H, OCH₂CH₂CH₂CH₃), 1.30–1.10 (2H, OCH₂CH₂CH₂CH₃), 0.83 (3H, t, *J* = 6.9, OC₃H₆CH₃); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.07 (s, 3F), -67.66 (s, 2F), -116.28 (dd, *J_{AB}* = 226.4 Hz, Δv =12.26, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 143.6, 128.5, 126.9, 121.3 (m), 120.9 (q, *J* = 272.5 Hz), 76.9, 76.8, 68.1, 35.6, 34.7, 31.4, 19.4, 13.9; FT-IR (neat): v_{max} 2961, 2936, 2875, 1667, 1494, 1392, 1339, 1303, 1249,

1219, 1180, 1141, 1077, 1057, 1013, 948, 893, 789, 701 cm⁻¹; EIHRMS: m/z 481.0708 (M⁺, C₁₈H₁₉ClF₇NO₂S requires 481.0713).

4g-major endo: colorless oil; 158.8 mg, 63%; ¹H NMR (300 MHz, CDCl₃): δ 7.32 – 7.19 (5H, m, ArH), 6.27 (1H, d, J = 2.7 Hz, =CH), 5.61 (1H, s, NCHO), 3.73 – 3.64 (1H, m, CHPh), 3.60 – 3.46 (1H, m, OCH(CH₂)₅), 2.51 (1H, ddd, J = 14.4, 9.0, 3.0 Hz, CH_aH_e), 2.36 (1H, d, J = 14.4 Hz, CH_aH_e), 1.82 – 1.05 (10H, m, OCH(CH₂)₅); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.97 (s, 3F), -68.42 (m, 2F), -117.15 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.40, 2F$); ¹³C NMR (100 MHz, CDCl₃): δ 143.6, 128.5, 128.2, 126.6, 121.7 (m), 120.6 (q, J = 272.2 Hz), 73.7, 35.4, 34.9, 32.6, 30.7, 25.6, 23.5, 23.1; FT-IR (neat): v_{max} 2937, 2860, 1668, 1605, 1494, 1454, 1337, 1303, 1251, 1180, 1139, 1056, 942, 896, 858, 789, 700 cm⁻¹; EIMS: (m/z, %): 408 (M⁺ – C₆H₁₁O, 4.09), 372 (M⁺ – C₂F₄Cl, 38.00), 324 (2.94), 290 (64.72), 246 (100.00), 225 (37.83), 183 (40.32), 83 (63.87), 55 (44.69); EIHRMS: m/z 507.0875 (M⁺, C₂₀H₂₁CIF₇NO₂S requires 507.0870).

4h-major endo: colorless oil, as a 10/1 mixture with the minor *endo* diastereomer; 107.4 mg, 46%; ¹H NMR (300 MHz, CDCl₃): δ 7.37–7.20 (5H, m, ArH), 6.22 (1H, d, *J* = 3.0 Hz, =C*H*), 5.64 (1H, s, NC*H*O), 5.34 (2H, d, *J* = 5.6 Hz, =C*H*₂), 4.25 (1H, s, C*H*Ph), 3.64 (1H, dq, *J* = 9.3, 6.9 Hz, OC*H*HCH₃), 3.45 (1H, dq, *J* = 9.3, 6.9 Hz,OC*H*HCH₃), 1.14 (3H, t, *J* = 6.9 Hz, OCH₂C*H*₃); ¹⁹F NMR (282 MHz, CDCl₃): δ -65.06 (s, 3F), -68.54 (s, 2F), -115.07 (dd, *J*_{AB} = 222.2 Hz, Δv = 9.86, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 141.7, 141.3, 128.6, 128.3, 127.1, 122.7, 120.6 (q, *J* = 272.5 Hz), 117.8, 80.3, 63.2, 44.0, 14.8; FT-IR (neat): v_{max} 3313, 2981, 2932, 1669, 1603, 1496, 1446, 1403, 1326, 1311, 1261, 1185, 1139, 1089, 1045, 934, 901, 790, 703 cm⁻¹; EIMS (*m*/*z*, %): 330 (M⁺ - C₂F₄Cl, 47.34), 282 (5.31), 236 (100.00), 216 (54.15), 115 (17.45), 91 (10.78), 77 (6.92); EIHRMS: *m*/*z* 465.0392 (M⁺, C₁₇H₁₅ClF₇NO₂S requires 465.0400).

4j-major endo: white solid, mp 61–63 °C; 172.4 mg, 65%; ¹H NMR (300 MHz, CDCl₃): δ 7.29–7.16 (2H, m,

ArH), 6.90–6.81 (2H, m, ArH), 6.21 (1H, d, J = 3.0 Hz, =CH), 5.45 (1H, s, NCHO), 4.14–4.04 (1H, m, CHPh), 3.85 (3H, s, OCH₃), 3.29 (1H, dd, J = 9.3, 6.3 Hz, OCHHCH(CH₃)₂), 3.10 (1H, dd, J = 9.3, 6.0 Hz, OCHHCH(CH₃)₂), 2.45 (1H, ddd, J = 14.4, 9.0, 2.7 Hz, CH_aH_e), 2.45 (1H, d, J = 14.4 Hz, CH_aH_e), 1.72–1.56 (1H, m, OCH₂CH(CH₃)₂), 0.77 (3H, d, J = 6.3 Hz, OCH₂CH(CH₃)₂), 0.72 (3H, d, J = 6.3 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.05 (s, 3F), -68.36 (m, 2F), -116.99 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.38$, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 156.0, 131.1, 129.8, 127.8, 121.4, 120.8 (q, J = 272.4 Hz), 120.1, 109.9, 77.2, 75.0, 55.2, 33.0, 28.6, 28.1, 19.2, 19.1; FT-IR (KBr): v_{max} 2960, 1662, 1602, 1493, 1472, 1338, 1301, 1249, 1195, 1181, 1141, 1121, 1056, 949, 863, 787, 751 cm⁻¹; EIHRMS: *m*/z 511.0818 (M⁺, C₁₉H₂₁ClF₇NO₃S requires 511.0819).

4k-major endo: colorless oil; 149.8 mg, 59%; ¹H NMR (300 MHz, CDCl₃): δ 7.19 (2H, J = 8.7 Hz, ArH), 6.80 (2H, J = 8.7 Hz, ArH), 6.21 (1H, d, J = 3.6 Hz, =CH), 5.44 (1H, s, NCHO), 3.77 (3H, s, OCH₃), 3.67–3.55 (1H, m, CHPh), 3.29 (1H, dd, J = 9.0, 6.9 Hz, OCHHCH(CH₃)₂), 3.11 (1H, dd, J = 9.3, 6.3 Hz, OCHHCH(CH₃)₂), 2.47 (1H, ddd, J = 14.7, 9.0, 3.3 Hz, CH_a H_e), 2.38 (1H, d, J = 14.7 Hz, CH_a H_e), 1.74–1.60 (1H, m, OCH₂CH(CH₃)₂), 0.78 (3H, d, J = 6.6 Hz, OCH₂CH(CH₃)₂), 0.74 (3H, d, J = 6.6 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.77 (s, 3F), -68.38 (s, 2F), -117.09 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.15$, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 158.3, 135.7, 129.3, 121.8 (m), 120.7 (q, J = 272.2 Hz), 113.7, 76.8, 75.1, 55.2, 34.7, 28.1, 18.8; FT-IR (neat): v_{max} 2961, 2934, 2876, 1668, 1612, 1514, 1466, 1394, 1340, 1304, 1255, 1180, 1140, 1058, 948, 896, 829, 789 cm⁻¹; EIHRMS: m/z 511.0821 (M⁺, C₁₉H₂₁ClF₇NO₃S requires 511.0819).

41-major endo: white solid, mp 44–46 °C; 159.0 mg, 64%; ¹H NMR (300 MHz, CDCl₃): δ 7.18 (2H, J = 7.8 Hz, ArH), 7.10 (2H, J = 7.8 Hz, ArH), 6.24 (1H, d, J = 3.0 Hz, =CH), 5.47 (1H, s, NCHO), 3.70–3.60 (1H, m, CHPh), 3.31 (1H, dd, J = 9.0, 6.3 Hz, OCHHCH(CH₃)₂), 3.14 (1H, dd, J = 9.0, 6.0 Hz, OCHHCH(CH₃)₂), 2.51 (1H, ddd, J = 14.7, 9.0, 3.3 Hz, CH_aH_e), 2.38 (1H, d, J = 14.7 Hz, CH_aH_e), 2.32 (3H, s, CH₃), 1.76–1.62 (1H, m, OCH₂CH(CH₃)₂), 0.80 (3H, d, J = 6.6 Hz, OCH₂CH(CH₃)₂), 0.77 (3H, d, J = 6.6 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR

(282 MHz, CDCl₃): δ -64.83 (s, 3F), -68.40 (s, 2F), -117.14 (dd, J_{AB} = 226.4 Hz, Δv = 12.17, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 140.5, 136.3, 129.0, 128.1, 125.0 (m), 121.9, 120.8 (q, J = 272.4 Hz), 76.8, 75.1, 35.0, 34.7, 28.1, 20.9, 19.2, 19.1; FT-IR (KBr): v_{max} 2963, 1664, 1513, 1338, 1305, 1249, 1119, 1057, 947, 817, 789 cm⁻¹; EIHRMS: m/z 495.0873 (M⁺, C₁₉H₂₁CIF₇NO₂S requires 495.0870).

4m-major endo: colorless oil; 172.9 mg, 67%; ¹H NMR (300 MHz, CDCl₃): δ 7.27 (2H, J = 8.7 Hz, ArH), 7.22 (2H, J = 8.7 Hz, ArH), 6.20 (1H, d, J = 3.3 Hz, =CH), 5.47 (1H, s, NCHO), 3.73–3.62 (1H, m, CHPh), 3.30 (1H, dd, J = 9.0, 6.3 Hz, OCHHCH(CH₃)₂), 3.12 (1H, dd, J = 9.0, 6.0 Hz, OCHHCH(CH₃)₂), 2.50 (1H, ddd, J = 14.4, 9.0, 3.0 Hz, CH_aH_e), 2.41 (1H, d, J = 14.4 Hz, CH_aH_e), 1.74–1.58 (1H, m, OCH₂CH(CH₃)₂), 0.77 (3H, d, J = 6.6 Hz, OCH₂CH(CH₃)₂), 0.74 (3H, d, J = 6.6 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.86 (s, 3F), -68.46 (s, 2F), -117.05 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.02, 2F$); ¹³C NMR (100 MHz, CDCl₃): δ 142.1, 132.7, 129.8, 128.6, 120.8 (q, J = 272.4 Hz), 120.3 (m), 76.9, 75.4, 34.9, 34.5, 28.3, 19.4, 19.3; FT-IR (neat): v_{max} 2963, 2877, 1667, 1493, 1395, 1342, 1303, 1249, 1179, 1058, 948, 896, 790 cm⁻¹; EIHRMS: *m/z* 515.0331 (M⁺, C₁₈H₁₈Cl₂ F₇NO₂S requires 515.0324).

4n-major endo: colorless oil; 165.7 mg, 59%; ¹H NMR (300 MHz, CDCl₃): δ 7.42 (2H, J = 8.7 Hz, ArH), 7.17 (2H, J = 8.7 Hz, ArH), 6.20 (1H, d, J = 3.3 Hz, =CH), 5.48 (1H, s, NCHO), 3.73–3.60 (1H, m, CHPh), 3.31 (1H, dd, J = 9.0, 6.3 Hz, OCHHCH(CH₃)₂), 3.13 (1H, dd, J = 9.0, 6.3 Hz, OCHHCH(CH₃)₂), 2.50 (1H, ddd, J = 14.4, 9.3, 2.7 Hz, CH_aH_e), 2.41 (1H, d, J = 14.4 Hz, CH_aH_e), 1.74–1.59 (1H, m, OCH₂CH(CH₃)₂), 0.78 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂), 0.74 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.78 (s, 3F), -68.39 (s, 2F), -116.97 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.27, 2F$); ¹³C NMR (100 MHz, CDCl₃): δ 142.4, 131.4, 130.0, 122.0, 120.6 (q, J = 272.8 Hz), 120.0 (m), 76.7, 75.1, 34.7, 34.3, 28.1, 19.2, 19.1; FT-IR (neat): v_{max} 2962, 2929, 2876, 1668, 1490, 1394, 1341, 1303, 1249, 1180, 1124, 1058, 1012, 948, 895, 789 cm⁻¹; EIMS ($m/z, %_0$): 424 (M⁺ – C₂F₄Cl, 31.72), 376 (6.24), 302 (60.22), 261 (29.46), 57 (100.00); EIHRMS: m/z 558.9818).

40-major endo: colorless oil; 108.52 mg, 46%; ¹H NMR (300 MHz, CDCl₃): δ 7.31 (1H, d, J = 2.1 Hz, ArH), 6.28 (1H, dd, J = 3.0, 2.1 Hz, ArH), 6.24 (1H, d, J = 3.3 Hz, ArH), 6.07 (1H, d, J = 3.3 Hz, =CH), 5.50 (1H, s, NCHO), 3.82–3.73 (1H, m, CHPh), 3.22 (1H, dd, J = 9.0, 6.3 Hz, OCHHCH₃), 3.13 (1H, dd, J = 9.0, 6.0 Hz,OCHHCH₃), 2.67 (2H, d, J = 14.7, CH_aH_e), 2.27 (1H, ddd, J = 14.7, 9.0, 2.7 Hz, CH_aH_e), 1.68–1.53 (1H, m, OCH₂CH(CH₃)₂), 0.73 (3H, d, J = 3.6 Hz, OCH₂CH(CH₃)₂), 0.71 (3H, d, J = 3.6 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.74 (s, 3F), -68.27 (dd, $J_{AB} = 183.3$ Hz, $\Delta v = 0.20$, 2F), -116.65 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.59$, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 154.9, 140.9, 120.6 (q, J = 272.3 Hz), 116.9 (q, J = 5.3 Hz), 110.3, 105.6, 76.4, 74.7, 69.8, 30.7, 29.2, 28.0, 19.0, 18.9; FT-IR (neat): v_{max} 2962, 2877, 1670, 1615, 1506, 1474, 1395, 1338, 1314, 1289, 1260, 1181, 1122, 1060, 1013, 948, 894, 790 cm⁻¹; EIMS (*m/z*, %): 336 (M⁺ – C₂F₄Cl, 12.31), 236 (100.00), 214 (25.35), 184 (29.00), 57 (41.27); EIHRMS: *m/z* 471.0501 (M⁺, C₁₆H₁₇CIF₇NO₃S requires 471.0506).

4p-major endo: white solid, mp 64–66 °C; 159.1 mg, 60%; ¹H NMR (300 MHz, CDCl₃): δ 7.99 (1H, d, J = 8.1 Hz, ArH), 7.91 (1H, d, J = 7.5 Hz, ArH), 7.77 (1H, dd, J = 6.9, 2.7 Hz, ArH), 7.61–7.47 (2H, m, ArH), 7.45–7.36 (2H, m, ArH), 6.39 (1H, d, J = 3.3 Hz, =CH), 5.48 (1H, s, NCHO), 3.50–3.41 (1H, m, CHPh), 3.31 (1H, dd, J = 8.7, 6.9 Hz, OCHHCH₃), 3.07 (1H, dd, J = 9.0, 6.0 Hz,OCHHCH₃), 2.56 (2H, d, J = 13.8, CH_aH_e), 2.70 (1H, ddd, J = 13.8, 9.9, 3.0 Hz, CH_aH_e), 1.69–1.56 (1H, m, OCH₂CH(CH₃)₂), 0.76 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂), 0.70 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.67 (s, 3F), -68.26 (s, 2F), -116.87 (dd, $J_{AB} = 226.7$ Hz, $\Delta v = 12.45$, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 138.4, 134.0, 130.4, 129.4, 127.5, 126.7, 126.3, 125.4, 125.2, 122.1, 121.1, 120.7 (q, J = 272.2 Hz), 77.0, 76.7, 75.1, 34.0, 30.1, 28.1, 19.2, 19.1; FT-IR (KBr): v_{max} 3064, 2961, 2933, 2876, 1943, 1668, 1600, 1511, 1473, 1396, 1340, 1305, 1247, 1178, 1140, 1059, 1013, 948, 896, 860, 798, 782, 651 cm⁻¹; EIMS (*m/z*, %): 531 (M⁺, 5.44), 348 (3.48), 275

(52.94), 274 (100.00), 148 (8.28), 127 (11.59), 57 (23.57); EIHRMS: m/z 531.0868 (M⁺, C₂₂H₂₁ClF₇NO₂S requires 531.0870).

4q-major endo: colorless oil; 99.5 mg, 38%; ¹H NMR (300 MHz, CDCl₃): $\delta7.32 - 7.24$ (2H, m, ArH), 7.23 - 7.14 (3H, m, ArH), 6.02 (1H, d, J = 3.3 Hz, =CH), 5.44 (1H, s, NCHO), 3.26 (1H, dd, J = 9.0, 6.9 Hz, OCHHPr^{*i*}), 3.17 (1H, dd, J = 9.3, 6.0 Hz, OCHHPr^{*i*}), 2.62 (2H, t = 6.9 Hz, CH₂CH₂CH₂Ph), 2.32 (1H, s (b), CHPh), 2.16 (1H, d, J = 14.4 Hz, CH_aH_e), (1H, ddd, J = 14.4, 7.8, 1.2 Hz, CH_aH_e), 1.84 - 1.58 (5H, m, CH₂CH₂CH₂Ph, OCH₂CH(CH₃)₂), 0.83 (3H, d, J = 6.9, OCH₂CH(CH₃)₂), 0.80 (3H, d, J = 6.9, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.42 (s, 3F), -68.14 (s, 2F), -116.56 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.57$, 2F); ¹³C NMR (125 MHz, CDCl₃): δ 142.0, 128.4, 126.0, 122.1, 120.8 (q, J = 272.5 Hz), 77.2, 74.7, 35.8, 35.1, 30.3, 29.0, 28.1, 19.3, 19.2; FT-IR (neat): v_{max} 2961, 2933, 2872, 1666, 1606, 1497, 1455, 1394, 1343, 1297, 1257, 1237, 1179, 1123, 1059, 946, 909, 788, 736, 700 cm⁻¹; EIMS (m/z, %): 388 (M⁺ - C₂F₄Cl, 11.96), 340 (1.73), 266 (18.39), 91 (100.00), 57 (47.29); EIHRMS: m/z 450.0532 (M⁺ - OBu^{*i*}, C₁₂H₁₆CIF₇NOS requires 450.0529).

4r-major endo: colorless oil; 73.9 mg, 32%; ¹H NMR (300 MHz, CDCl₃): δ 6.04 (1H, d, J = 3.9 Hz, =CH), 5.45 (1H, s, NCHO), 3.28 (1H, dd, J = 9.0, 6.9 Hz, OCHHPr^{*i*}), 3.18 (1H, dd, J = 9.3, 6.0 Hz, OCHHPr^{*i*}), 2.29 (1H, s (b), CHPh), 2.16 (1H, d, J = 14.1 Hz, CH_aH_e), 2.02 (1H, dd, J = 14.1, 8.4 Hz, CH_aH_e), 1.84–1.68 (1H, m, OCH₂CH(CH₃)₂), 1.67–1.54 (2H, m, CH₂(CH₂)₂CH₃), 1.44–1.27 (4H, m, CH₂(CH₂)₂CH₃), 0.91 (3H, t, J = 6.9, (CH₂)₃CH₃), 0.85 (6H, d, J = 6.9, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.59 (s, 3F), -68.29 (s, 2F), -116.78 (dd, $J_{AB} = 226.4$ Hz, $\Delta v = 12.53$, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 122.5 (m), 120.8 (q, J = 272.2 Hz), 77.2, 74.6, 35.2, 30.4, 30.3 29.3, 28.1, 22.5, 19.2, 19.1, 13.9; FT-IR (neat): v_{max} 2963, 2934, 2876, 1666, 1470, 1395, 1344, 1297, 1179, 1142, 1056, 1012, 948, 898, 789 cm⁻¹; EIMS (m/z, %): 388 (M⁺ – OBu^{*i*}, 5.25), 326 (M⁺ – C₂F₄Cl, 19.09), 204 (21.28), 57 (100.00); EIHRMS: m/z 461.1028 (M⁺, C₁₆H₂₃ClF₇NO₂S requires 461.1026).

4s-major endo: colorless oil; 117.2 mg, 47%; ¹H NMR (300 MHz, CDCl₃): δ 7.35–7.19 (5H, m, ArH), 6.24 (1H, s, =C*H*), 5.50 (1H, s, NCHO), 3.74–3.68 (1H, m, C*H*Ph), 3.43 (1H, dd, *J* = 9.0, 6.3 Hz, OC*H*HPr^{*i*}), 3.14 (1H, dd, *J* = 9.0, 6.3 Hz, OCH*H*Pr^{*i*}), 2.49 (1H, ddd, *J* = 14.4, 9.3, 2.7 Hz, C*H*_aH_e), 2.27 (1H, d, *J* = 14.4 Hz, CH_aH_e), 1.69 (1H, m, OCH₂C*H*(CH₃)₂), 0.78 (3H, d, *J* = 6.9, OCH₂CH(CH₃)₂), 0.74 (3H, d, *J* = 6.9, OCH₂CH(C*H*₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -50.13 (dd, *J*_{AB} = 230.7 Hz, Δv = 15.81, 2F), -68.29 (s, 2F), -116.61 (dd, *J*_{AB} = 230.7 Hz, Δv = 12.65, 2F); ¹³C NMR (100 MHz, CDCl₃) δ 143.6, 128.3, 128.2, 126.6.5, 119.6 (m), 76.9, 76.8, 75.3, 35.3, 34.5, 28.2, 19.3, 19.2; FT-IR (neat): v_{max} 2962, 2876, 2212, 1656, 1604, 1496, 1473, 1455, 1392, 1342, 1288, 1258, 1235, 1216, 1178, 1152, 1121, 1056, 1022, 949, 898, 788, 700 cm⁻¹; EIMS: (*m*/*z*, %): 424 (M⁺ – OBu^{*i*}, 4.32), 362 (M⁺ – C₂F₄Cl, 37.81), 314 (7.82), 240 (48.70), 91 (32.52), 77 (24.71), 57 (100.00); EIHRMS: *m*/*z* 497.0415 (M⁺, C₁₈H₁₉Cl₂F₆NO₂S requires 497.0418).

4t-major endo: pale yellow solid, mp 51–53 °C; 180.5 mg, 68%; ¹H NMR (300 MHz, CDCl₃): δ 7.38–7.19 (5H, m, ArH), 6.69 (1H, J = 3.0 Hz, =CH), 5.41 (1H, J = 2.4 Hz, NCHO), 5.26–5.10 (1H, m, CO₂CH₂CH(CH₃)₂), 3.68 (1H, d, J = 9.3 Hz, CHPh), 3.43 (1H, dd, J = 9.6, 6.9 Hz, OCHHPr^{*i*}), 3.22 (1H, dd, J = 9.3, 6.0 Hz, OCHHPr^{*i*}), 2.66 (1H, ddd, J = 15.0, 10.2, 3.6 Hz, CH_aH_e), 2.37 (1H, d, J = 15.0 Hz, CH_aH_e), 1.83–1.69 (1H, m, OCH₂CH(CH₃)₂), 1.32 (6H, d, J = 6.3 Hz, OCH₂CH(CH₃)₂), 0.83 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂), 0.81 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂); 0.81 (3H, d, J = 6.9 Hz, OCH₂CH(CH₃)₂); 19 F NMR (282 MHz, CDCl₃): δ -67.32 (dd, $J_{AB} = 181.3$ Hz, $\Delta v = 0.38$, 2F), -116.43 (dd, $J_{AB} = 226.7$ Hz, $\Delta v = 11.95$, 2F); 13 C NMR (100 MHz, CDCl₃): δ 162.0, 144.3, 130.8, 128.4, 126.8, 126.7, 74.9, 70.0, 36.7, 35.8, 28.2, 21.7, 21.6, 19.3, 19.2; FT-IR (KBr): v_{max} 2960, 2874, 1716, 1640, 1493, 1468, 1455, 1390, 1377, 1286, 1245, 1220, 1173, 1088, 1057, 1024, 974, 896, 789, 768, 701 cm⁻¹; EIHRMS: *m/z* 456.0663 (M⁺ – Pr^{*i*}, C₁₈H₁₉CIF₄NO₄S requires 531.0870).

4v-major endo: white solid, mp 109–111 °C; 131.2 mg, 56.6%; ¹H NMR (300 MHz, CDCl₃): δ 7.51 (1H, s, =CH), 7.37–7.21 (5H, m, ArH), 4.93 (1H, s, NCHO), 3.85 (1H, d, *J* = 7.2 Hz, CHPh), 3.22 (1H, dd, *J* = 8.3, 6.5 Hz, OCHHPr^{*i*}), 2.53 (1H, ddd, *J* = 13.8, 2.7, 2.4 Hz, CH_aH_e), 2.26 (1H, ddd, *J* = 13.8, 7.2, 2.7 Hz, CH_aH_e), 0.93 (1H, m, OCH₂CH(CH₃)₂), 0.69 (3H, d, *J* = 6.9, OCH₂CH(CH₃)₂), 0.60

(3H, d, J = 6.9, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -67.37 (s, 2F), -116.58 (dd, $J_{AB} = 230.7$ Hz, Δν = 8.43, 2F); ¹³C NMR (125 MHz, CDCl₃): δ 140.1, 133.2, 128.4, 127.8, 127.0, 118.1, 95.5, 83.8, 75.7, 37.2, 34.2, 28.2, 18.9, 18.8; FT-IR (KBr): v_{max} 2960, 2874, 2212, 1631, 1449, 1386, 1365, 1268, 1142, 1105, 1058, 1012, 976, 894, 799, 747, 698 cm⁻¹; Anal. Calcd. for C₁₈H₁₉ClF₄N₂O₂S: C, 49.26; H, 4.36; N, 6.38. Found: C, 49.39; H, 4.63; N, 6.19.

4v-minor endo: colorless oil, 42.8 mg, 19.5%; ¹H NMR (300 MHz, CDCl₃): δ 7.39–7.15 (6H, m, ArH, =C*H*), 5.15 (1H, t, *J* = 3.3 Hz, NCHO), 3.82 (1H, dd, *J* = 6.6, 3.6 Hz, CHPh), 3.20 (1H, dd, *J* = 8.4, 6.5 Hz, OCHHPr^{*i*}), 2.92 (1H, dd, *J* = 8.4, 6.5 Hz, OCHHPr^{*i*}), 2.54 (1H, dt, *J* = 13.8, 3.9 Hz, CH_a*H*_e), 2.27 (1H, ddd, *J* = 13.8, 7.2, 2.7 Hz, CH_aH_e), 1.48 (1H, m, OCH₂CH(CH₃)₂), 0.66 (3H, d, *J* = 6.3, OCH₂CH(CH₃)₂), 0.58 (3H, d, *J* = 6.3, OCH₂CH(CH₃)₂); ¹⁹F NMR (282 MHz, CDCl₃): δ -68.07 (m, 2F), -115.25 (dd, *J*_{AB} = 222.4 Hz, Δv =11.73, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 140.0, 135.7, 128.5, 127.6, 127.1, 118.1, 94.9, 83.1, 76.1, 37.6, 34.8, 28.1, 18.8; EIMS (*m*/*z*, %): 438 (M⁺, 1.15), 365 (5.58), 303 (49.82), 229 (43.02), 203 (46.96), 181 (50.13), 140 (64.96), 57 (100.00); EIHRMS: *m*/*z* 438.0801 (M⁺, C₁₈H₁₉ClF₄N₂O₂S requires 438.0792).

 $(S_s, 2S, 4R)$ -6-major endo: $[\alpha]_D^{28} = +131.8^{\circ}$ (CHCl₃, *c* 1.0); Enantiomeric excess: > 99.9%, HPLC (OD column) 0.7 mL/min (n-hexane/isopropanol = 98/2): t_R 8.0 (minor), t_R 8.8 (major).

Transformations of Cycloadduct.



Compound (S_s , 2*S*, 4*R*)-**6** (70 mg, 0.15 mmol) was dissolved in THF (2 mL) and the mixture was refluxed overnight. After removal of the solvent, the residue was purified by column chromatography to give product **7** as a colorless oil (17.4 mg, 52% yield); ¹H NMR (300 MHz, CDCl₃): δ 8.77 (1H, d, *J* = 5.1 Hz), 7.90 (1H, s), 7.71 – 7.63 (3H, m), 7.57–7.45 (3H, m); ¹⁹F NMR (282 MHz, CDCl₃): δ -67.97 (s, 3F); ¹³C NMR (100 MHz, CDCl₃): δ 150.1, 136.5, 129.5, 129.0, 126.7, 123.8, 121.7, 120.6 (q, *J*_{AB} = 271.4 Hz), 118.1 (m); FT-IR (neat): v_{max} 2956, 2926, 2854, 1693, 1606, 1460, 1378, 1336, 1261, 1183, 1149, 1089, 1023, 803, 762, 697 cm⁻¹; LRMS (ESI): *m/z* 224.0 (M⁺+1); EIHRMS: *m/z* 223.0607 (M⁺, C₁₂H₈F₃N requires 223.0609).



To a solution of compound (S_s , 2S, 4R)-6 (0.1 mmol) in CH₂Cl₂ (1 mL), was added BCl₃ (dissolved in CH₂Cl₂, 0.1 mmol) at 0 °C. The mixture was stirred at that temperature for 1 h and then quenched with 5 mL saturated aqueous NH₄Cl solution. The resulted mixture was extracted with CH₂Cl₂ (5 mL \times 3). The combined organic

phase was dried over Na₂SO₄ and concentrated. The residue was purified by flash chromatography to afford **8** as a white solid (24.7 mg, 58% yield); mp 114–115 °C; ¹H NMR (300 MHz, CDCl₃): δ 7.40–7.18 (5H, m, ArH), 6.22 (1H, s, =CH), 5.93(1H, s, NCH(OH)), 3.86 (1H, m, CHPh), 2.67 (1H, s, NCH(OH)), 2.43 (1H, dddd, *J* = 13.8, 6.6, 2.7, 1.2 Hz, CH_aH_e), 1.84 (1H, t, *J* = 13.8 Hz, CH_aH_e); ¹⁹F NMR (282 MHz, CDCl₃): δ -65.22 (s, 3F), -68.38 (s, 2F), -114.53 (dd, *J_{AB}* = 222.5 Hz, Δv =14.75, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 140.9, 129.1, 127.6, 127.5, 122.6 (m), 120.6 (q, *J_{AB}* = 271.6 Hz), 77.3, 73.7, 36.8, 34.4; FT-IR (KBr): v_{max} 3421, 1662, 1495, 1455, 1395, 1303, 1207, 1183, 1153, 1126, 1105, 1053, 811, 701 cm⁻¹; EIMS (*m/z*, %): 290 (M⁺ – C₂F₄Cl, 40.89), 242 (5.94), 224 (32.52), 183 (100.00), 77 (24.89); EIHRMS: *m/z* 425.0089 (M⁺, C₁₄H₁₁CIF₇NO₂S requires 425.0087); [α]_D²⁷ = +53.6° (CHCl₃, *c* 1.0).



To a solution of compound (S_s , 2*S*, 4*R*)-**6** (0.3 mmol) and Et₃SiH (0.9 mmol) in CH₂Cl₂ (3 mL), was added BCl₃ (dissolved in CH₂Cl₂, 0.9 mmol) at 0 °C. The mixture was stirred at room temperature for 2 h and then quenched with saturated aqueous NH₄Cl solution. The resulted mixture was extracted with CH₂Cl₂ (6 mL × 3). The combined organic phase was dried over Na₂SO₄ and concentrated. The residue was purified by flash chromatography to afford **9** as a colorless oil (78.2 mg, 65% yield); ¹H NMR (300 MHz, CDCl₃): δ 7.40–7.17 (5H, m, ArH), 6.06 (1H, d, *J* = 2.4 Hz, =C*H*), 4.04 (1H, d, *J* = 13.2 Hz), 3.71–3.60 (1H, m, C*H*Ph), 3.50 (1H, t, *J* = 11.7 Hz), 2.34–2.23 (1H, m), 1.98–1.56 (1H, m); ¹⁹F NMR (282 MHz, CDCl₃): δ -64.97 (s, 3F), -68.58 (s, 2F), -114.84 (dd, *J_{AB}* = 222.5 Hz, Δv =10.73, 2F); ¹³C NMR (100 MHz, CDCl₃): δ 141.7, 128.9, 127.4, 127.3, 120.4 (q, *J_{AB}* = 271.8 Hz), 119.7 (dd, *J_{AB}* = 5.3 Hz, Δv = 0.05), 39.9, 38.7, 31.0; FT-IR (neat): v_{max} 2937, 2871, 1656, 1494, 1454, 1390, 1347, 1294, 1263, 1183 (b), 1135 (b), 1059, 1015, 967, 793, 701, 642 cm⁻¹; EIMS (*m/z*, %): 274 (M⁺ – C₂F₄Cl, 100.00), 226 (19.36), 224 (34.83), 183 (32.45), 91 (26.73), 77 (10.95); EIHRMS: *m/z* 409.0132 (M⁺, C₁₄H₁₁ClF₇NOS requires 409.0138); [α]_D²⁵ = +117.0° (CHCl₃, *c* 1.0).



To a solution of compound 9 (0.3 mmol) in MeOH (5 mL) was added HCl/Et₂O (1M, 5 mL), and the mixture was stirred at 50 $^{\circ}$ C for 1h. The reaction mixture was then evaporated. The residue was dissolved in CH₂Cl₂, and washed with saturated aqueous NaHCO₃ solution. The organic phase was dried and concentrated to give imine **10** without further purification.

The above imine was dissolved in MeOH (3 mL), NaBH₃CN (0.75 mmol) and a few drops of glacial AcOH was added at 0 °C. The resulting mixture was stirred at room temperature for 2h. Then the reaction mixture was

concentrated and CH₂Cl₂ (5 mL) was added. The organic phase was washed with saturated aqueous NaHCO₃ solution, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography to afford **11** as a colorless oil⁴ (48.9 mg, 71% total yield); ¹H NMR (400 MHz, CDCl₃): δ 7.36–7.28 (2H, m, ArH), 7.27–7.19 (3H, m, ArH), 3.36–3.22 (2H, m, H-2 and H-6), 2.82 (1H, td, *J* = 12.4, 2.5 Hz, H-6), 2.65 (1H, tt, *J* = 12.4, 3.2 Hz, H-4), 2.05 (1H, d, *J* = 12.4 Hz, H-3), 1.86 (1H, d, *J* = 12.4 Hz, H-5), 1.76 (1H, s, NH), 1.67 (1H, qd, *J* = 12.4, 4.0 Hz, H-3), 1.64 (1H, q, *J* = 12.4 Hz, H-5); ¹⁹F NMR (282 MHz, CDCl₃): δ -77.73 (s, 3F); ¹³C NMR (100 MHz, CDCl₃): δ 145.0, 128.6, 126.7, 126.6, 125.6 (q, *J*_{AB} = 273.6 Hz), 58.4 (q, *J*_{AB} = 28.6 Hz), 46.1, 41.6, 33.1, 32.3; FT-IR (neat): v_{max} 3335, 2929, 2848, 1603, 1494, 1453, 1395, 1373, 1270, 1230, 1176, 1147, 1129, 1100, 814, 759, 263.78 in⁻¹; EIMS (*m*/*z*, %): 230 (M⁺ + H, 8.76), 229 (M⁺, 58.07), 160 (100.00), 104 (20.37), 91 (20.09), 77 (14.85), 56 (71.78); EIHRMS: *m*/*z* 229.1079 (M⁺, C₁₂H₁₄F₃N requires 229.1078); [α]_D²³ = -6.5° (MeOH, *c* 1.4); Enantiomeric excess: 98 %, HPLC (Lux 5µ Cellulose-2 column) 0.3 mL/min (n-hexane/isopropanol = 99/1): t_R 18.3 (minor), t_R 19.4 (major).

Determination of the Stereochemistry of the Products

a) Stereochemistry endo

It is well-known that the Diels-Alder reaction of N-sulfinyl-1-aza-1,3-dienes takes place with very high *endo*-selectivity⁵. We have confirmed this stereochemistry by X-ray diffraction analysis of 4c (see below). The data of X-ray structure of 4c are found at the end of the Supporting Information.



b) Relative Stereochemistry of Product 8

The Lewis acid-promoted nucleophilic replacement of the alkoxy group is known to proceed with inversion of configuration^{5c, 5d}. We have confirmed this stereochemistry by X-ray diffraction analysis of (\pm) -7 (see below). Data of X-ray structure of (\pm) -7 are found at the end of the Supporting Information.



c) Relative Stereochemistry of Product 11

The relative stereochemistry of **11** has been established by NMR. ¹H NMR experiments allowed proton assignment, while the 2D-NOESY experiments were decisive for the determination of relative stereochemistry. Some critical NOE contacts are shown in the Figure below. On the other hand, the relative stereochemistry is in agreement with the anticipated⁶ axial addition of hydride to the specific half-chaired imine intermediate **10**.



References

¹ a) R. J. Andrew, J. M. Mellor, *Tetrahedron* 2000, *56*, 7261. b) M. Hojo, R. Masuda, Y. Kokuryo, H. Shioda, S. Matsuo, *Chem. Lett.* 1976, 499. c) M.Hojo, R. Masuda, E. Okada, S. Sakaguchi, H. Narumiya, K. Morimoto, *Tetrahedron Lett.* 1989, *30*, 6173. d) M. A. P. Martins, D. J. Emmerich, C. M. P. Pereira, W. Cunico, M. Rossato, N. Zanatta, H. G. Bonacorso, *Tetrahedron Lett.* 2004, *45*, 4935. e) X.-J. Wang, Y. Zhao, J.-T. Liu, *Org. Lett.* 2007, *9*, 1343 and references cited therein.
² X.-J. Wang, J.-T. Liu, *Tetrahedron* 2005, *61*, 6982.

³ V. D. Romanenko, C. Thoumazet, V. Lavallo, F. S. Tham, G. Bertrand, Chem. Commun. 2003, 1680.

⁴ Gheorghe et al. *Tetrahedron* **2007**, *63*, 7187.

⁵ a) W. L. Corbett, T. T. Curran, A. M. Kasper, D. L. Boger, J. Am. Chem. Soc. 1991, 113, 1713. b) W. L. Corbett, D. L. Boger, J. Org. Chem. 1993, 2068. c) R. C. Clark, S. S. Pfeiffer, D. L. Boger, J. Am. Chem. Soc. 2006, 2587. d) J. Esquivias, R. G. Arrayás, J. C. Carretero, J. Am. Chem. Soc. 2007, 129, 1480.

⁶ G. Stork, D. Q. Niu, A. Fujimoto, E. R. Koft, J. M. Balkovec, J. R. Tata, G. R. Dake J. Am. Chem. Soc. 2001, 123, 3239 and references therein.



































































































